In rare disorders, there are often no standard therapy recommendations. Patients with refractory disease may require novel experimental approaches. Applied as second- up to fourth-line treatment, lenalidomide (10-25 mg perorally on days 1-21 in a 28-day cycle) was used in our cohort of four adult patients with aggressive, multisystem and relapsing diseases. Complete and long-lasting remissions (more than 1 year, no maintenance therapy) were achieved in patients with Langerhans cell histiocytosis (11 cycles, combination with dexamethasone and etoposide, consolidated by allogeneic blood stem cell transplant) and plasma-cell Castleman disease (15 cycles, monotherapy). Mixed response with complete disappearance of brain infiltrates was reached in Erdheim-Chester disease (6 cycles, monotherapy) and gastrointestinal bleeding was well controlled in multiple angiomatosis (9 cycles, combination with thalidomide). For disease activity evaluation each patient underwent fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography scan imaging, which was complemented by clinical and laboratory investigations.

000      

00000naa a2200000 a 4500

001      

bmc17015185

003      

CZ-PrNML

005      

20170426100423.0

007      

ta

008      

170426s2013 it d f 000 0|eng||

009      

AR

024    7_

$a 10.1700/1377.15326 $2 doi

035    __

$a (PubMed)24362880

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a it

100    1_

$a Szturz, Petr $7 xx0146033

245    10

$a Salvage lenalidomide in four rare oncological diseases / $c P Szturz, Z Adam, Z Rehak, R Koukalova, L Kren, M Moulis, M Krejci, J Mayer

520    9_

$a In rare disorders, there are often no standard therapy recommendations. Patients with refractory disease may require novel experimental approaches. Applied as second- up to fourth-line treatment, lenalidomide (10-25 mg perorally on days 1-21 in a 28-day cycle) was used in our cohort of four adult patients with aggressive, multisystem and relapsing diseases. Complete and long-lasting remissions (more than 1 year, no maintenance therapy) were achieved in patients with Langerhans cell histiocytosis (11 cycles, combination with dexamethasone and etoposide, consolidated by allogeneic blood stem cell transplant) and plasma-cell Castleman disease (15 cycles, monotherapy). Mixed response with complete disappearance of brain infiltrates was reached in Erdheim-Chester disease (6 cycles, monotherapy) and gastrointestinal bleeding was well controlled in multiple angiomatosis (9 cycles, combination with thalidomide). For disease activity evaluation each patient underwent fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography scan imaging, which was complemented by clinical and laboratory investigations.

590    __

$a bohemika - dle Pubmed

650    02

$a dospělí $7 D000328

650    12

$a inhibitory angiogeneze $x terapeutické užití $7 D020533

650    02

$a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971

650    12

$a compassionate use trials $7 D057176

650    02

$a přežití po terapii bez příznaků nemoci $7 D018572

650    02

$a Erdheimova-Chesterova nemoc $x farmakoterapie $7 D031249

650    12

$a hyperplazie velkých lymfatických uzlin $x farmakoterapie $x patologie $7 D005871

650    02

$a transplantace hematopoetických kmenových buněk $7 D018380

650    12

$a histiocytóza z Langerhansových buněk $x farmakoterapie $x patologie $7 D006646

650    02

$a lidé $7 D006801

650    02

$a magnetická rezonanční tomografie $7 D008279

650    02

$a mužské pohlaví $7 D008297

650    02

$a lidé středního věku $7 D008875

650    02

$a pozitronová emisní tomografie $7 D049268

650    02

$a vzácné nemoci $7 D035583

650    02

$a retrospektivní studie $7 D012189

650    12

$a záchranná terapie $x metody $7 D016879

650    02

$a thalidomid $7 D013792

650    02

$a počítačová rentgenová tomografie $7 D014057

650    02

$a autologní transplantace $7 D014182

650    02

$a homologní transplantace $7 D014184

650    02

$a výsledek terapie $7 D016896

700    1_

$a Adam, Zdeněk, $d 1953- $7 jn19981000018

700    1_

$a Řehák, Zdeněk $7 xx0101561

700    1_

$a Koukalová, Renata $7 xx0130184

700    1_

$a Křen, Leoš, $d 1966- $7 xx0081918

700    1_

$a Moulis, Mojmír $7 xx0121681

700    1_

$a Krejčí, Marta, $d 1969- $7 jx20080512017

700    1_

$a Mayer, Jiří, $d 1960- $7 nlk20000083651

773    0_

$t Tumori $g Roč. 99, č. 5 (2013), s. e251-e256 $p Tumori $x 0300-8916 $w MED00010709

773    0_

$p Tumori $g 99(5):e251-6, 2013 Sep-Oct

910    __

$a ABA008 $y 4 $z 0

990    __

$a 20170426100742 $b ABA008

991    __

$a 20170426100742 $b ABA008

999    __

$a ok $b bmc $g 1202238 $s 975969

BAS    __

$a 3

BMC    __

$a 2013 $b 99 $c 5 $d e251-e256 $x MED00010709 $i 0300-8916 $m Tumori

GRA    __

$a NT12215 $p MZ0

LZP    __

$a NLK 2015-B/lp